Hygieia, a Livonia, MI-based digital therapeutics company for insulin therapy, extended its Series B round to $22M.
The round was led by Firstime Ventures and additional investment from two unnamed strategic partners.
The company intends to use the funds to explore additional ways to bring d-Nav Technology to more insulin users, for safe, effective insulin therapy.
Led by CEO Eran Bashan, Hygieia is the developer of d-Nav, a FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav’s AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body’s changing insulin needs.
The company is building a national network of diabetes care centers driven by the d-Nav Technology. Hygieia’s d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes is now in Michigan, Texas, Arizona, and North Carolina, with more states available soon. The program fits into endocrinology practice operations to improve patient outcomes while providing an added revenue stream.
The program is covered by Medicare, most commercial health plans, and many Medicaid plans.
FinSMEs
02/05/2023